All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Hematology Drugs in Phase III Clinical Development in UNITED KINGDOM

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Akari Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study

Contact the Supplier

Lead Product(s): Nomacopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

All patients treated with nomacopan achieved the primary endpoint of transfusion independence.

Shield Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

China licence agreement for Feraccru/Accrufer

Contact the Supplier

Lead Product(s): Ferric Maltol

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical

Deal Size: $62.8 million Upfront Cash: $11.4 million

Deal Type: Licensing Agreement January 08, 2020

Details:

Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .